Stock ZLAB ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Zai Lab Limited

Equities

ZLAB

US98887Q1040

Real-time Estimate Cboe BZX
Other stock markets
 03:00:29 2024-04-30 pm EDT 		5-day change 1st Jan Change
15.82 USD -1.83% Intraday chart for Zai Lab Limited +4.66% -42.10%
Apr. 17 Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading MT
Apr. 11 Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities
AQ
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint
AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BU
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases
AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
BU
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
BU
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
BU
Zai Lab Announces Participation in March Investor Conference
BU
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
BU
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
BU
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
BU
Zai Lab Announces Participation in January Investor Conference
BU
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
AQ
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
BU
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
GL
Zai Lab Announces Participation in November Investor Conferences
GL
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. News Zai Lab Limited
  5. Press Releases